Therefore, we aimed to determine whether norepinephrine (NE), the primary neurotransmitter of the sympathetic nervous system (SNS), which is elevated in conditions such as hypertension, diabetes, and obesity, may upregulate SGLT1 expression (Figure 6). Here, SLC5A1 is linked to diabetes mellitus.